iSpecimen Inc. (NASDAQ:ISPC) Sees Large Increase in Short Interest

Posted by Brian Himes on Jun 13th, 2026

iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) was the target of a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 241,056 shares, a growth of 113.6% from the May 14th total of 112,840 shares. Based on an average daily trading volume, of 386,118 shares, the days-to-cover ratio is presently 0.6 days. Approximately 19.1% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ISPC. Wall Street Zen upgraded iSpecimen to a “sell” rating in a research note on Saturday, May 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

View Our Latest Stock Report on iSpecimen

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iSpecimen stock. Virtu Financial LLC acquired a new position in iSpecimen Inc. (NASDAQ:ISPC – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned about 0.65% of iSpecimen as of its most recent SEC filing. Institutional investors own 13.62% of the company’s stock.

iSpecimen Stock Performance

NASDAQ ISPC remained flat at $2.75 during trading on Friday. The company’s stock had a trading volume of 108,522 shares, compared to its average volume of 235,423. The company has a market capitalization of $3.96 million, a P/E ratio of -0.04 and a beta of 1.62. The firm’s fifty day moving average is $4.39 and its 200 day moving average is $9.94. iSpecimen has a fifty-two week low of $2.54 and a fifty-two week high of $127.20.

iSpecimen (NASDAQ:ISPC – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($6.66) earnings per share for the quarter. The business had revenue of $0.16 million during the quarter. iSpecimen had a negative return on equity of 584.65% and a negative net margin of 1,080.16%.

iSpecimen Company Profile

(Get Free Report)

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.